Genetically adjusted PSA levels for prostate cancer screening

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kachuri, Linda, Hoffmann, Thomas J., Jiang, Yu, Berndt, Sonja I., Shelley, John P., Schaffer, Kerry R., Machiela, Mitchell J., Freedman, Neal D., Huang, Wen-Yi, Li, Shengchao A., Easterlin, Ryder, Goodman, Phyllis J., Till, Cathee, Thompson, Ian, Lilja, Hans, Van Den Eeden, Stephen K., Chanock, Stephen J., Haiman, Christopher A., Conti, David V., Klein, Robert J., Mosley, Jonathan D., Graff, Rebecca E., Witte, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287565/
https://www.ncbi.nlm.nih.gov/pubmed/37264206
http://dx.doi.org/10.1038/s41591-023-02277-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287565/
https://www.ncbi.nlm.nih.gov/pubmed/37264206
http://dx.doi.org/10.1038/s41591-023-02277-9

Ejemplares similares